Search

The article reports that Canada will move in the opposite direction of the approach on isotope production through MDS Nordion and Atomic Energy of Canada Ltd. (AECL). According to Alan J. Kuperman, director of the Nuclear Proliferation Prevention Program at the University of Texas, the 4 general recommendations are a rejection across-the-board of the Nordion/AECL approach. An overview of the recommendations on solving the problem is presented.

The article focuses on the call of MDS Nordion, the Canadian life sciences company, for the federal government to determine that it would fix 2 nuclear reactors that can produce medical isotopes in Canada. It cites that MDS Nordion hired Atomic Energy of Canada Ltd. (AECL) for the design and building of 2 nuclear reactors. It also offers insights on the Multipurpose Applied Physics Lattice Experiment (MAPLE) project of MDS Nordion which was cancelled due to technical issues.

The article reports on the difficulties being faced by the Canada's Multipurpose Applied Physics Lattice Experiment (MAPPLE) reactors dedicated to the production of medical isotopes. The MAPPLE is capable of supplying Canada with medical isotopes used for diagnostics and the destruction of tumours through gamma rays or drugs, yet its operation is still unclear due to some problems in terms of finances. The MAPPLE has been vested with the Atomic Energy of Canada Ltd. (AECL) but the government moved to private it in the late 1980s and bought in 1991 in the form of MDS Health Group Inc. for $165 million. Moreover, renegotiation between MDS Nordion and AECL took place in 2005 and agreed on the transfer of ownership of the Dedicated Isotope Facility to AECL in exchange for $68 million.

The article reports on the demand by MDS Nordion, a medical isotope company, for the Canadian government and Atomic Energy of Canada Ltd. to fulfil contractual obligations made in 1996 to build two isotope production reactors to replace the National Research Universal reactor. Atomic Energy agreed to build the project, called Maple, to be paid for by MDS Nordion. On June 2, 2009, Atomic Energy announced that it had started the process of removing fuel rods from the National Research Universal reactor as part of repairing the reactor.

The article reports on the halting of the development of the Multipurpose Applied Physics Lattice Experiment (MAPLE) reactors in Canada. The Atomic Energy of Canada Ltd. declared their plans to halt the commissioning of the reactors which were seen as the new supply of the country's medical isotope. Focus will instead be redirected to the maintenance of the National Research Universal reactor. Factors contributing to the termination of MAPLE include a budget which has exceeded five hundred million dollars and design and regulatory problems.

The article reports on the rise of Canadian Hospitals during the shortage of medical isotope supply as determined by Andrew Ross of the Halifax and Nova Scotia―based Queen Elizabeth II Health Sciences Centre. It mentions that there had been no advance warning or news from Atomic Energy of Canada Ltd. that there was a possible medical isotope supply interruption which led to the dilemma of many hospitals in Canada. It discusses that hospitals will not be able to operate well if there are no medical isotopes, for these isotopes are being used in diagnosing ailments like heart disease and cancer. Because of this incident, hospital staffs joined hand-in-hand by means of sharing dwindling supplies and working tirelessly just to accommodate patients.